ArticleJournal of neuro-oncology2025
Clinical and genomic factors differ in pediatric and adult pilocytic astrocytoma: a single-center experience with over 350 patients.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pilocytic astrocytoma in pediatric and adult patients: a single-center analysis of 650 cases.Virchows Archiv : an international journal of pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePilocytic astrocytoma (PA) is rare in adults despite being the most common pediatric brain tumor. KIAA1549::BRAF fusion and BRAF p.V600E mutation are common in PA, yet prognostic impact of these alterations remains uncertain. We highlight clinical characteristics and tumor genomics in PA across the lifespan, exploring factors associated with disease progression.
methodsPediatric and adult patients who underwent biopsy or resection of PA from 2000 to 2023 were retrospectively studied. Clinical data and tumor genomics were collected, and progression/recurrence-free survival (PRFS) analysis was performed.
resultsWe identified 334 pediatric and 32 adult PA patients. Tumor location distribution did not differ between groups, with the cerebellum being the predominant location (59.3% pediatric and 50.0% adult). Gross total resection (GTR) was more common in children (79.1% versus 62.1%, p = 0.04). KIAA1549::BRAF fusion was more frequent in children (59.6% versus 23.1%, p = 0.02). BRAF p.V600E mutations were rarer in both groups (14.6% pediatric versus 8.3% adult, p = 1). In children, GTR was associated lower rates of tumor progression/recurrence (9.8% versus 41.2%, p < 0.001) and longer PRFS (p < 0.001). Cerebellar tumors in children were also associated with lower rates of tumor progression/recurrence (13.1% versus 31.6%, p < 0.001) and longer PRFS (p < 0.001). No operative/genomic predictors of PRFS were identified in adults. Overall rate of tumor progression/recurrence did not differ between groups (21.3% pediatric versus 15.6% adult, p = 0.65).
conclusionClinical characteristics and factors influencing tumor progression/recurrence differ in children and adults with PA. This work highlights current knowledge gaps on age-related differences in PA, providing clinical and genomic context for future studies.
Indexed as
Identifiers
40775485What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.